• Vaccine Name: Brucella abortus Omp16 L7/L12 recombinant influenza viral vector vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009352
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Antigen: Omp16; L7/L12
• Adjuvant: Montadine Gel01
• Preparation: Influenza viral vector expressing Brucella abortus proteins Omp16 and L7/L12 combined with Montadine Gel01 adjuvant. (Tabynov et al, 2016)
  Recombinant influenza viral vector expressing Brucella abortus Omp16 and L7/L12 proteins; no adjuvant reported. (Ryskeldinova et al, 2021)
• Description: This study analyzed the duration of antigen-specific humoral and T-cell immune responses and protectiveness of a recently-developed influenza viral vector Brucella abortus vaccine expressing Omp16 and L7/L12 proteins with Montadine Gel01 adjuvant in cattle. Efficacy: Prime-boost vaccination provided significant protection against B. abortus infection at 3, 6, 9, and 12 months post-booster; 57.1 to 71.4% of vaccinated animals showed no signs of infection; severity and colonization rates were significantly lower in vaccinated diseased animals; good protection also observed in pregnant heifers, their fetuses, and calves; 71.4% of vaccinated heifers calved successfully versus 100% abortion in controls. Immune response: Both humoral (IgG ELISA titers with IgG2a predominance) and pronounced T-cell responses (lymphocyte stimulation index and IFN-γ production) were induced and maintained up to 12 months post-booster vaccination. (Tabynov et al, 2016)
  The Flu-BA vaccine, a novel influenza viral vector based Brucella abortus vaccine, was introduced for use in cattle in Kazakhstan in 2019. Efficacy: Vaccine effectiveness against Brucella abortus 544 infection was 75% in calves, 60% in heifers, and 60% in adult cows; vaccinated animals showed greater protection and no clinical disease including abortion; Brucella were not isolated from calves of vaccinated cattle challenged during pregnancy. Immune response: Vaccinated animals in all age groups demonstrated increased IgG antibody responses against Brucella Omp16 and L7/L12 proteins, with calves showing the greatest increase in humoral responses; no signs of influenza infection or reduced milk production were observed; influenza viral vector was not recovered from nasal swabs or milk. (Ryskeldinova et al, 2021)

Cattle Response

• Vaccination Protocol: Prime-boost vaccination of cattle (heifers) with Flu-BA vaccine; immune responses measured by IgG ELISA titers, lymphocyte stimulation index, IFN-γ production; protection assessed by Brucella isolation and infection indices at multiple time points up to 12 months post-booster vaccination. (Tabynov et al, 2016)
• Immune Response: Both humoral (IgG ELISA titers with IgG2a predominance) and pronounced T-cell responses (lymphocyte stimulation index and IFN-γ production) were induced and maintained up to 12 months post-booster vaccination. (Tabynov et al, 2016)
• Efficacy: Prime-boost vaccination provided significant protection against B. abortus infection at 3, 6, 9, and 12 months post-booster; 57.1 to 71.4% of vaccinated animals showed no signs of infection; severity and colonization rates were significantly lower in vaccinated diseased animals; good protection also observed in pregnant heifers, their fetuses, and calves; 71.4% of vaccinated heifers calved successfully versus 100% abortion in controls. (Tabynov et al, 2016)
• Description: Prime-boost vaccination of cattle (heifers) with Flu-BA vaccine; immune responses measured by IgG ELISA titers, lymphocyte stimulation index, IFN-γ production; protection assessed by Brucella isolation and infection indices at multiple time points up to 12 months post-booster vaccination. (Tabynov et al, 2016)

Cattle Response

• Immune Response: Vaccinated animals in all age groups demonstrated increased IgG antibody responses against Brucella Omp16 and L7/L12 proteins, with calves showing the greatest increase in humoral responses; no signs of influenza infection or reduced milk production were observed; influenza viral vector was not recovered from nasal swabs or milk. (Ryskeldinova et al, 2021)
• Challenge Protocol: Safety and efficacy were evaluated in male and female cattle at different ages (calves 5-7 months, heifers 15-17 months, cows 6-7 years) including pregnant animals; experimental challenge with Brucella abortus strain 544 was performed. (Ryskeldinova et al, 2021)
• Efficacy: Vaccine effectiveness against Brucella abortus 544 infection was 75% in calves, 60% in heifers, and 60% in adult cows; vaccinated animals showed greater protection and no clinical disease including abortion; Brucella were not isolated from calves of vaccinated cattle challenged during pregnancy. (Ryskeldinova et al, 2021)
• Description: Safety and efficacy were evaluated in male and female cattle at different ages (calves 5-7 months, heifers 15-17 months, cows 6-7 years) including pregnant animals; experimental challenge with Brucella abortus strain 544 was performed. (Ryskeldinova et al, 2021)